Evidence map›Paper›PMID 33863238›Full record

ReviewAnnual review of biomedical engineering2021

Vascularized Microfluidics and Their Untapped Potential for Discovery in Diseases of the Microvasculature.

David R Myers, Wilbur A Lam

Open access · hybridAbstract readReview
In one paragraph

Review in Annual review of biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Engineering Organ-on-a-Chip Systems for Vascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Why platelet mechanotransduction matters for hemostasis and thrombosis.Journal of thrombosis and haemostasis : JTH · 2023
    Review
  18. Article
  19. Review
  20. Exploring Endothelial Expansion on a Chip.Sensors (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

David R MyersThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, USA; email: david.myers@emory.edu, wilbur.lam@emory.edu.
Wilbur A LamThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, USA; email: david.myers@emory.edu, wilbur.lam@emory.edu.
Children's Healthcare of Atlanta · USThe Wallace H. Coulter Department of Biomedical Engineering · US

Funding

Engineering biophysical microtechnologies for hematologic applications in health and diseaseR35HL145000 · NHLBI · EMORY UNIVERSITY · PI LAM, WILBUR A · 2019 to 2025
$5.0M
Platelet-like particles for augmenting hemostasisR01HL130918 · NHLBI · UNIVERSITY OF VIRGINIA · PI BARKER, THOMAS HARRISON, LAM, WILBUR A · 2016 to 2019
$2.7M
Leveraging platelet contraction cytometry for immune thrombocytopeniaR01HL155330 · NHLBI · EMORY UNIVERSITY · PI MYERS, DAVID RICHARD · 2021 to 2025
$1.9M
Wearable Microchip for Assessing Global HemostatsisK25HL141636 · NHLBI · EMORY UNIVERSITY · PI MYERS, DAVID RICHARD · 2019 to 2023
$788k
Platelet contraction cytometry as a novel assay of platelet functionR21EB026591 · NIBIB · EMORY UNIVERSITY · PI MYERS, DAVID RICHARD · 2018 to 2020
$693k
iPPSIS: implanted Passive Pressure Sensor Interrogated with (ultra)-SoundR21EB031545 · NIBIB · EMORY UNIVERSITY · PI LINDSEY, BROOKS D, MYERS, DAVID RICHARD · 2021 to 2021
$450k
NHLBI NIH HHS K25 HL141636NHLBI NIH HHS R01 HL130918NHLBI NIH HHS R01 HL155330NHLBI NIH HHS R35 HL145000NIBIB NIH HHS R21 EB026591NIBIB NIH HHS R21 EB031545
6 · The paper itself

Abstract

Microengineering advances have enabled the development of perfusable, endothelialized models of the microvasculature that recapitulate the unique biological and biophysical conditions of the microcirculation in vivo. Indeed, at that size scale (<100 μm)-where blood no longer behaves as a simple continuum fluid; blood cells approximate the size of the vessels themselves; and complex interactions among blood cells, plasma molecules, and the endothelium constantly ensue-vascularized microfluidics are ideal tools to investigate these microvascular phenomena. Moreover, perfusable, endothelialized microfluidics offer unique opportunities for investigating microvascular diseases by enabling systematic dissection of both the blood and vascular components of the pathophysiology at hand. We review (

Indexed as

MicrofluidicsTissue EngineeringMicrovesselsbloodendothelialmicrofluidicsmicrovasculaturepathology

Identifiers

PMID33863238
PMCPMC8785195
OpenAlexW3154247747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.